Neuroblastoma+4
Not recruitingStudy on Ribociclib, Topotecan, and Temozolomide for Children and Young Adults (12 months - 21 years) with Relapsed or Refractory Neuroblastoma and Solid Tumors
Study on Ribociclib, Topotecan, and Temozolomide for Children and Young Adults (12 months - 21 years) with Relapsed or Refractory Neuroblastoma and Solid Tumors
- Disease:NeuroblastomaRhabdomyosarcoma+3
- Substances:RibociclibTemozolomide+1
Denmark- Participants:0–17 years · 18–64 years
- Substances:Ribociclib
- Sponsor:Novartis Pharma AG
















